| Year |
Citation |
Score |
| 2023 |
Madajewski B, Boatman MA, Martinez I, Carter JH, Bey EA. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer. Genes. 14. PMID 36980879 DOI: 10.3390/genes14030607 |
0.601 |
|
| 2023 |
Raddatz AD, Furdui CM, Bey EA, Kemp ML. Single-Cell Kinetic Modeling of β-Lapachone Metabolism in Head and Neck Squamous Cell Carcinoma. Antioxidants (Basel, Switzerland). 12. PMID 36978989 DOI: 10.3390/antiox12030741 |
0.322 |
|
| 2020 |
Starcher CL, Pay SL, Singh N, Yeh IJ, Bhandare SB, Su X, Huang X, Bey EA, Motea EA, Boothman DA. Targeting Base Excision Repair in Cancer: NQO1-Bioactivatable Drugs Improve Tumor Selectivity and Reduce Treatment Toxicity Through Radiosensitization of Human Cancer. Frontiers in Oncology. 10: 1575. PMID 32974194 DOI: 10.3389/Fonc.2020.01575 |
0.322 |
|
| 2019 |
Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg M, Bey EA, Boothman DA. NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30617135 DOI: 10.1158/1078-0432.Ccr-18-2560 |
0.33 |
|
| 2016 |
Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, ... ... Bey EA, et al. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell. 30: 940-952. PMID 27960087 DOI: 10.1016/J.Ccell.2016.11.006 |
0.367 |
|
| 2016 |
Madajewski B, Boatman MA, Chakrabarti G, Boothman DA, Bey EA. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. Molecular Cancer Research : McR. 14: 14-25. PMID 26553038 DOI: 10.1158/1541-7786.Mcr-15-0207-T |
0.606 |
|
| 2012 |
Huang X, Dong Y, Bey EA, Kilgore JA, Bair JS, Li LS, Patel M, Parkinson EI, Wang Y, Williams NS, Gao J, Hergenrother PJ, Boothman DA. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Research. 72: 3038-47. PMID 22532167 DOI: 10.1158/0008-5472.Can-11-3135 |
0.381 |
|
| 2010 |
Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, Kessinger CW, Carnevale KA, Bornmann WG, Boothman DA, Gao J. β-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy Cancer Research. 70: 3896-3904. PMID 20460521 DOI: 10.1158/0008-5472.Can-09-3995 |
0.319 |
|
| 2005 |
Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, Boothman DA, Oberley LW, Cullen JJ. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biology & Therapy. 4: 95-102. PMID 15662131 DOI: 10.4161/Cbt.4.1.1382 |
0.306 |
|
| 2004 |
Bey EA, Xu B, Bhattacharjee A, Oldfield CM, Zhao X, Li Q, Subbulakshmi V, Feldman GM, Wientjes FB, Cathcart MK. Protein kinase C delta is required for p47phox phosphorylation and translocation in activated human monocytes. Journal of Immunology (Baltimore, Md. : 1950). 173: 5730-8. PMID 15494525 DOI: 10.4049/Jimmunol.173.9.5730 |
0.602 |
|
| 2002 |
Zhao X, Bey EA, Wientjes FB, Cathcart MK. Cytosolic phospholipase A2 (cPLA2) regulation of human monocyte NADPH oxidase activity: cPLA2 affects translocation but not phosphorylation of p67phox and p47phox Journal of Biological Chemistry. 277: 25385-25392. PMID 12101222 DOI: 10.1074/Jbc.M203630200 |
0.613 |
|
| 2002 |
Bey EA, Cathcart MK. Antisense oligodeoxyribonucleotides: A better way to inhibit monocyte superoxide anion production? Methods in Enzymology. 353: 421-434. PMID 12078515 DOI: 10.1016/S0076-6879(02)53066-4 |
0.616 |
|
| 2000 |
Bey EA, Cathcart MK. In vitro knockout of human p47phox blocks superoxide anion production and ldl oxidation by activated human monocytes Journal of Lipid Research. 41: 489-495. PMID 10706597 |
0.557 |
|
| Show low-probability matches. |